Chemical Industries Far East (C05) H2 2025 earnings summary

Executive summary

• FY2025 revenue fell to $65.4m from $72.6m; reported net loss was $21.5m, versus $4.9m profit in FY2024.

• Intense competition, industry pricing pressure and lower offtake drove weaker results; cash flow from operations remained positive at $9.1m.

Financial highlights

• Revenue was $65.374m, down from $72.583m; gross profit was $3.837m versus $5.632m, with gross margin pressure from lower sales and operating costs.

• Reported loss before tax was $22.102m; income tax credit of $645,000 brought net loss to $21.457m, versus FY2024 net profit of $4.865m.

• Other expenses included $10.1m PPE impairment, $6.2m onerous-contract provision and $0.7m investment-property fair-value loss.

• Depreciation rose to $6.710m from $6.081m; higher depreciation following CAPEX contributed to the loss.

• EPS was a loss of 28.25 cents, compared with earnings of 6.41 cents in FY2024.

Outlook and guidance

• A proposed 10-year, $150m supply agreement for a key customer's new plant expansion was in final signing stages and is expected to lift performance over the next few years.

• Cost rationalisation and right-sizing aim to streamline operations and reduce overheads, with significant savings targeted in future years.

• Priorities include exploring renewable energy sources, improving energy efficiency, developing higher-value downstream products and expanding speciality chemicals through a new distribution agreement.

• Geopolitical and trade tensions create uncertainty; recession risk cannot be ruled out.